We also demonstrated the characteristics and functionality of these MSLN.CAR-IL-15 iNK cells through comprehensive in vitro and in vivo experiments, including validating CAR expression and profiling iNK cell biomarkers, and demonstrated the tumor killing efficacy of these engineered iNK cells against MSLN-positive solid tumors. The gene discussed is MSLN; the disease is neoplasm.